InsiderSignal.AI

InsiderSignal.ai

LQDA - Liquidia Corp

Insider Sale by Saggar Rajeev (Chief Medical Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Saggar Rajeev, serving as Chief Medical Officer at Liquidia Corp (LQDA), sold 9,220 shares at $38.37 per share, for a total transaction value of $353,771.00. Following this transaction, Saggar Rajeev now holds 173,270 shares of LQDA.

This sale represents a 5.00% decrease in Saggar Rajeev's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 13, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, April 14, 2026, 1 day after the trade was made.

Liquidia Corp operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Saggar Rajeev

Saggar Rajeev

Chief Medical Officer

Rajeev Saggar, M.D., is the Chief Medical Officer at Liquidia Corporation (LQDA), a role he assumed on July 18, 2022, where he oversees research, clinical development, medical affairs, and regulatory affairs.[[1]](https://www.marketscreener.com/quote/stock/LIQUIDIA-CORPORATION-45064777/news/Liquidia-Appoints-Rajeev-Saggar-M-D-as-Chief-Medical-Officer-40774522/)[[2]](https://www.nasdaq.com/press-release/liquidia-appoints-rajeev-saggar-m.d.-as-chief-medical-officer-2022-06-20) With over 20 years as a practicing pulmonologist, Dr. Saggar has authored more than 60 peer-reviewed publications focused on pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD).[[1]](https://www.marketscreener.com/quote/stock/LIQUIDIA-CORPORATION-45064777/news/Liquidia-Appoints-Rajeev-Saggar-M-D-as-Chief-Medical-Officer-40774522/) His career highlights include serving as Interim Chief of the Division of Pulmonary Critical Care at the University of Arizona College of Medicine, Phoenix, and as Medical Director of the Pulmonary Hypertension and Fibrosis Programs and Lung Transplant Program at Banner University Medical Center, Phoenix, where he was a Principal Investigator in the pivotal INSPIRE study of YUTREPIA.[[1]](https://www.marketscreener.com/quote/stock/LIQUIDIA-CORPORATION-45064777/news/Liquidia-Appoints-Rajeev-Saggar-M-D-as-Chief-Medical-Officer-40774522/)[[3]](https://www.sec.gov/Archives/edgar/data/1819576/000110465922073264/tm2219020d1_8k.htm) Prior to Liquidia, he was Vice President of Clinical Development at Theravance Biopharma, managing clinical development across respiratory diseases including pulmonary fibrosis, asthma, COPD, and COVID-19.[[1]](https://www.marketscreener.com/quote/stock/LIQUIDIA-CORPORATION-45064777/news/Liquidia-Appoints-Rajeev-Saggar-M-D-as-Chief-Medical-Officer-40774522/)

View full insider profile →

Trade Price

$38.37

Quantity

9,220

Total Value

$353,771.00

Shares Owned

173,270

Trade Date

Monday, April 13, 2026

2 days ago

SEC Filing Date

Tuesday, April 14, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Liquidia Corp

Company Overview

No company information available
View news mentioning LQDA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5640078

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime